AMT Medical Secures $25 Million in Series B Funding to Revolutionize Coronary Artery Bypass Surgery

AMT Medical B.V., a clinical-stage medtech innovator, announced a $25 million Series B financing round led by Bender Analytical Holding B.V. (BAH). New investors Invest-NL, and the European Innovation Council (EIC) joined existing backers Oost NL and informal angels in the round. The funding accelerates the development of AMT’s ELANA® Heart Bypass System, a minimally invasive solution designed to replace traditional open-heart bypass surgery, ultimately leading to robot-assisted keyhole surgery compatible with surgical robots from industry leaders.

 The new funding will enable the company to pursue key initiatives, including CE marking and initial clinical trials in the United States in open and robotic settings.

 Paradigm Shift in Cardiac Surgery: Key innovations

The ELANA® Heart Bypass System will enable surgeons to perform the most state-of-the-art coronary artery bypass grafting (CABG) with arterial (instead of venous) bypass grafts and through small chest incisions without stopping the heart or using a heart-lung machine, which eliminates stroke risks and other complications and reduces postoperative recovery times. This contrasts starkly with conventional methods requiring sternotomy (chest cracking), complex suturing and long recovery times. With these improvements, the system further aims to significantly reduce costs associated with CABG procedures. 

The sutureless anastomosis technique utilizes a proprietary clip and an excimer laser to connect blood vessels without manual suturing, enabling precise, rapid, and standardized and reproducible graft integration while minimizing complications.

Additionally, the system achieves over 50% cost reduction when used in a robotic setting. This is driven by shorter operating room times, reduced hospital stays (patients can return home within days), fewer complications, and faster surgeon mastery compared to traditional coronary artery bypass grafting. 

Key initiatives

Following this financing round, the capital will drive AMT’s running initiatives: Completing AMT Medical’s European first-in-human trial evaluating the system during - still - open chest CABG procedures with a beating heart. Results of the trial will be available towards the end of 2025 and presented/published to the surgical community. With this data, AMT foresees obtaining CE Marking by 2026 for use during open surgical CABG procedures, either through sternotomy or via a minimally invasive thoracotomy (MIDCAB). Furthermore, clinical trials will be started in the United States in open and robotic setting.

Rutger Tulleken, CEO & Co-Founder of AMT Medical, commented:

“This financing validates our mission to make open-heart bypass obsolete. By enabling same-day discharge bypass procedures, we’re not just improving outcomes – we’re redefining cardiovascular care.”

Johan Bender, CEO of Bender Analytical Holding:

“We are proud to support AMT as they work toward FDA clearance to bring their technology to the market in the U.S. This marks a key milestone in improving patient outcome”